Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 2—February 2016
Dispatch

Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin

Margaret M. WilliamsComments to Author , Kathryn Sen, Michael R. Weigand, Tami H. Skoff, Victoria A. Cunningham, Tanya A. Halse, M. Lucia Tondella, and CDC Pertussis Working Group
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.M. Williams, M.R. Weigand, T.H. Skoff, M.L. Tondella); New York State Department of Health, Albany, New York, USA (K.A. Sen); Livingston County Health Department, Mt. Morris, New York, USA (V.A. Cunningham); Wadsworth Center, Albany (T.A. Halse)

Main Article

Figure 1

Western blot of pertussis toxin (Pt) expression in Bordetella pertussis Tohama I, I979, FR3749, and 3 additional recent isolates. All isolate lanes were loaded with 10-μg of protein, extracted after 48 hours’ growth. Protein was transferred with the iBlot Dry Blotting system (Invitrogen, Carlsbad, CA, USA). The primary antibody consisted of 1b7 anti-PTX S1 monoclonal antibody at a concentration of 20 μg/mL diluted in 0.01 M PBS/Tween with 5% milk. The secondary antibody was a FITC-conjugated goa

Figure 1. Western blot of pertussis toxin (Pt) expression in Bordetella pertussis Tohama I, I979, FR3749, and 3 additional recent isolates. All isolate lanes were loaded with 10-μg of protein, extracted after growth for 48 hours. Protein was transferred with the iBlot Dry Blotting system (Invitrogen, Carlsbad, CA, USA). The primary antibody consisted of 1b7 anti-PTX S1 monoclonal antibody at a concentration of 20 μg/mL diluted in 0.01 M PBS/Tween with 5% milk. The secondary antibody was a FITC-conjugated goat anti-mouse pAb from AbCam, diluted 1:1,000 with 0.01 M PBS/Tween with 5% milk. Lane 1, benchmark protein ladder, 6–180 kDa (Life Technologies, Grand Island, NY, USA); lane 2, Pt positive control, 2 μg; lane 3, empty; lanes 4 and 5, J024 (pertactin (Prn)+/Pt+); lanes 6 and 7, I979 (Prn-/Pt-); lanes 8 and 9, Tohama I (Prn+/Pt+); lanes 10 and 11, I978 (Prn-/Pt+); lanes 12 and 13, FR3749 (Prn+/Pt-); lanes 14 and 15, I974 (Prn-/Pt+).

Main Article

1Members of the CDC Pertussis Working Group are listed at the end of this article.

Page created: January 15, 2016
Page updated: January 15, 2016
Page reviewed: January 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external